The Hope App Study

Sponsor
See Yourself Health LLC (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05729516
Collaborator
(none)
150
2
17

Study Details

Study Description

Brief Summary

This research study will test how a computer program (called the Hope App) teaches diabetes care skills for older adults with diabetes. The study will compare those who receive diabetes education (10 educational modules and monthly health coaching) through the research program with those who receive care as usual.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Hope App immersive learning and telehealth platform
N/A

Detailed Description

The Hope App offers a simple, high-impact, engaging, and immersive telehealth experience with the potential to become a ubiquitous diabetes management tool to transform diabetes patients into high performing drivers of their own care.

The research team aims to scale the platform, develop features that are important to aging adults, and run a clinical trial to validate the Hope App's health benefits.

  • Specific Aim 1: Develop the Hope App's state-of-the-art immersive patient engagement experience with automated onboarding, social networking and gamified DSME/S features to support long-term patient retention. In doing so, usability testing will be performed to ensure patient-facing features on the platform and patient-facing content and curriculum materials are functioning and well received by participants.

  • Specific Aim 2: Develop the Hope App's predictive analytic capabilities for population health management.

  • Specific Aim 3: Conduct a clinical validation trial of the Hope App intervention on six-month clinical outcomes (Hemoglobin A1c), patient reported outcomes (diabetes distress) and engagement outcomes (patient retention, adherence to self-care behaviors).

The research team intends to deliver a scalable Hope App platform with a usable patient engagement portal designed for older adults and achieve decreases in blood glucose levels (HbA1c) and depressive burden, and sustained patient engagement.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a wait-list control study design. Participants are assigned to one of two groups at random (intervention and wait list) for 6 months. After 6 months, participants in the wait list group are able to receive the intervention.This is a wait-list control study design. Participants are assigned to one of two groups at random (intervention and wait list) for 6 months. After 6 months, participants in the wait list group are able to receive the intervention.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Hope App: An Immersive Telehealth Solution for Older Adults With Diabetes
Anticipated Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Apr 1, 2024
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Immediate Treatment Group (ITG)

ITG participants receive access to the Hope App, a newly designed immersive learning and telehealth application designed to deliver engaging diabetes care and self-management education and support for older adults with diabetes. ITG participants also complete data collection (surveys and HbA1c measurements) at baseline, 3 months after baseline, and 6 months after baseline.

Behavioral: Hope App immersive learning and telehealth platform
As part of the Hope App intervention, participants attend 10 skills sessions related to diabetes self-management. ITG participants will also receive monthly health coaching calls. After 6 months of active participation, participants enter a maintenance period, during which programming concludes but continued access to the program materials remains.

No Intervention: Wait List Control (WLC)

WLC participants receive care as usual for 6 months. They will complete data collection (surveys and HbA1c measurements) at baseline, 3 months after baseline, and 6 months after baseline. After 6 months, WLC participants will gain access to the Hope App and receive diabetes programming and health coaching for the remaining 6 months.

Outcome Measures

Primary Outcome Measures

  1. change in glycemic control [baseline and 6 months]

    change in HbA1c values recorded from point-of-care tests or in the electronic health record at visits. A mean change of 0.5% will be the a priori determined clinically meaningful minimum improvement from baseline to 6 months.

Secondary Outcome Measures

  1. changes in self-reported diabetes distress [baseline to 3 months; 3 months to 6 months; baseline to 6 months]

    self-reported changes in diabetes distress scale

  2. self-reported weight change [baseline to 3 months; 3 months to 6 months; baseline to 6 months]

    self-reported weight change in pounds

  3. changes in participant engagement [baseline to 3 months; 3 months to 6 months; baseline to 6 months]

    proportion of utilization metrics met (frequency of use, feature interactions)

  4. changes in self-management adherence [baseline to 3 months; 3 months to 6 months; baseline to 6 months]

    self-reported changes in the 11-item Summary of Diabetes Self-Care Activities Assessment. The first 10 items are summed to a total score and averaged to 5 scale scores; the scales are General Diet, Specific Diet, Exercise, Blood-Glucose Testing, and Foot Care. Mean number of days will be assessed for self-management behaviors. The 11th question assess smoking status (yes(1), no(0)).

  5. changes in medication adherence scale [baseline to 3 months; 3 months to 6 months; baseline to 6 months]

    self-reported changes in the Morisky Medication Adherence scale. There are 4-item and 8-item versions with higher scores indicating higher levels of adherence to medication.

  6. changes in depressive burden symptoms [baseline to 3 months; 3 months to 6 months; baseline to 6 months]

    self-reported changes in Patient Health Questionnaire (PHQ)-9. PHQ-9 total score over nine items ranges from 0-24, with higher scores indicative of greater depressive symptom burden.

  7. changes in general anxiety symptoms [baseline to 3 months; 3 months to 6 months; baseline to 6 months]

    self-reported changes in General Anxiety Disorder (GAD)-7 questionnaire. GAD-7 total score over seven items ranges from 0-21, with higher scores indicative of increased symptoms of anxiety.

  8. changes in coping skills [baseline to 3 months; 3 months to 6 months; baseline to 6 months]

    self-reported changes to Brief Resilient Coping Scale. The total score over 4 items ranges from 4-20, with higher scores indicative of high resilient coping.

  9. changes in perceived support from healthcare providers [baseline to 3 months; 3 months to 6 months; baseline to 6 months]

    self-reported changes in Healthcare Climate Questionnaire

  10. changes in perceived competence [baseline to 3 months; 3 months to 6 months; baseline to 6 months]

    self-reported changes in Perceived Competence in Diabetes Scale. There are 4-items on a Likert scale from 1-7 with higher scores representing a higher degree to which people with diabetes feel they can self-manage their diabetes. The mean score is used as a summary score.

  11. changes in perceived diabetes self-efficacy [baseline to 3 months; 3 months to 6 months; baseline to 6 months]

    self-reported changes in diabetes self-efficacy scale. There are 8 items on a Likert scale from 1 to 10. The score for the scale is the mean of the eight items. Higher number is indicative of higher self-efficacy.

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • aged 65 years and above

  • diagnosis of type 2 diabetes

  • English-speaking

  • baseline blood sugar value (HbA1c) of 7.5%

  • Internet access

Exclusion Criteria:
  • aged less than 65 years

  • non English-speaking

  • unable to provide informed consent

  • diagnosis of type 1 diabetes

  • unable to use a computer or mobile device

  • medical condition for which participation is contraindicated (dialysis, pregnancy, use of insulin pump)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • See Yourself Health LLC

Investigators

  • Principal Investigator: Suzanne Mitchell, MD, MS, See Yourself Health LLC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
See Yourself Health LLC
ClinicalTrials.gov Identifier:
NCT05729516
Other Study ID Numbers:
  • 2022/06/30
First Posted:
Feb 15, 2023
Last Update Posted:
Feb 15, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by See Yourself Health LLC

Study Results

No Results Posted as of Feb 15, 2023